Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes
Coadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR) to levodopa, levodopa-induced postsynap...
Main Authors: | C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2008-12-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996108001721 |
Similar Items
-
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01) -
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
by: Thomas Müller, et al.
Published: (2022-04-01) -
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01) -
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease
by: Shih-Chen Fu, et al.
Published: (2022-04-01) -
How Does Entacapon Affect Homocysteine Levels?
by: Gönül Akdağ, et al.
Published: (2021-06-01)